Related Experiment Video
Updated: Oct 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology
Manuel Anguita Sánchez1, Almudena Castro Conde2, Alberto Cordero Fort3
1Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
Insights
Lipid-lowering therapy is crucial for cardiovascular prevention. PCSK9 inhibitors offer a new, effective treatment for dyslipidemia, significantly reducing cardiovascular risk in patients who don't meet treatment goals.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Lipid-lowering therapy is vital for cardiovascular disease prevention, particularly secondary prevention of ischemic heart disease.
- Current treatments and lifestyle changes often fail to meet guideline-recommended lipid targets in many patients.
Framework:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel therapeutic class for managing dyslipidemia.
- These agents effectively reduce low-density lipoprotein cholesterol (LDL-C) levels.
Implementation:
- PCSK9 inhibitors have received approval from Spanish regulatory agencies for clinical use.
- Their application targets selected patient groups at high cardiovascular risk.
Implications:
- The introduction of PCSK9 inhibitors expands treatment options for dyslipidemia.
- This advancement aims to improve cardiovascular outcomes by achieving stricter lipid management goals.
Abstract:
Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management

